"Medical HeadlineJun" Sanofi/Regenerative Yuan Kevzara Treatment of New Crown Pneumonia Phase 3 Clinical Failure.

(2020/07/03) The new edition of the Pharmacopeia was officially announced to affect all Chinese medicine enterprises; Heng Rui, Renfu "grab food" 10 billion anaesthetic market! TOP10 products only 1 over review; China Sea, AstraZenecaOn July 2, local time, Sanofi and Regenerative Announced the results of the third phase of Kevzara's treatment of COVID-19The results showed that in patients with COVID-19 severe illness who required mechanical ventilation, the Combination of Kevzara 400mg and the best supportive treatment did not reach the primary and secondary endpoints compared to the best supported treatment alonethe results of the second phase of The 200mg and 400mg doses of Kevzara were not encouragingOn July 2,, the State Drug Administration and the State Health and Care Commission issued the Announcement on the Release of the 2020 Edition of the Pharmacopoeia of the People's Republic of China (No78 of 2020)According to the announcement, the 2020 edition of the Pharmacopoeia will be implemented from December 30 this yearWith the implementation of the new drug code, the pharmaceutical industry, especially the Chinese medicine industry, will usher in a round of major changesthe use of Chinese herbs is more than medicinalrecently, Jiangxi Province informed the implementation of the state-organized drug centralized procurement and use of the work, since March, Jiangxi Province every month will announce the first batch of 4 plus 7 national expansion of the province's implementationThe first batch of 4 plus 7 national expansion began to implement at the end of 2019, the current landing has been six months, the second batch of national collection landing soon and some varieties affected by the epidemic, so that the first batch of 4 plus 7 expansion of the situation, perhaps more representative of the 4-7 model extended to the national scope, the actual implementation of the situationDoes this mean that the unselected variety has completely lost its market? On June 20,, the 2020 Wuhan University Graduation Ceremony was held in the playground below the mountainIn the words of Principal Dou Xiankang, the graduation ceremony has overcome many difficulties, but just hope to let this graduate sorry lessAccording to official statements, this year's graduation ceremony at Wuhan University was "mainly online and offline as a supplement" to strictly control the number of people presentOnly 660 graduates were allowed to attend the ceremony, and ambulances were even arranged at the ceremony site outbreak salso had an impact on further education , Hengrui Pharmaceuticals' class 1 new drug injection with toluene sulfonate rematorial second indication (colonoscopy sedation) was approved, the product was approved for sale in December last year Yichang Manfu Pharmaceuticals' injection of benzene sulfonate remaline submitted a new class 1 application for listing in the review and approval In recent years, sales of end-use chemical anesthetics in public medical institutions in China have exceeded 10 billion, and sales of three products, such as propofol emulsion injections and inhalation of heptafluorane, have exceeded 1.5 billion yuan in TOP10 products Hengrui Class 1 new drug to the next city , the U.S "Pharmaceutical Managers" magazine recently announced its 2020 top 50 pharmaceutical companies The list is based on the global sales of prescription drugs for each pharmaceutical company in 2019, and is a more visual representation of the strength of each pharmaceutical business pharmaceutical companies' overall investment in new drug research and development remains at a high level.